Downregulation of CYP39A1 Serves as a Novel Biomarker in Hepatocellular Carcinoma with Worse Clinical Outcome

Figure 4

CYP39A1 protein expression in HCC and noncancerous liver tissues and its immunohistochemical staining in representative tissue specimens. (a) Immunohistochemical staining of CYP39A1 proteins in representative liver tissue specimens. Left bottom corner represents cancer tissues and top right corner represents noncancer tissues. DAB staining (brown); nuclear counterstaining (hematoxylin); original magnification, ×100; (b) CYP39A1 protein positive rate in adjacent noncancerous liver tissues and HCC tissues (, cancer vs. noncancerous tissues). Statistical analysis was performed by the chi-squared test; (c)–(e) Expression of CYP39A1 in representative tumor cells of HCC ((c) , (d) , and (e) ); (f) Expression of CYP39A1 in representative normal hepatocytes ((f) ). DAB staining (brown); nuclear counterstaining (hematoxylin); original magnification, ×200. Among them, (c) and (d) were defined as negative expression of CYP39A1, and (e) and (f) were defined as positive expression of CYP39A1.

(a)

(b)

(c)

(d)

(e)

(f)